Strawn Arnold & Associates, Ltd. is a premier provider of executive search to the life sciences and healthcare industries. Our reputation has been built through executing searches for directors of governance boards, all levels of general management, as well as selected functional experts. Many of our Partners are recognized as “best in class” in their market segments. With nearly four decades of service and experience, Strawn Arnold & Associates, Ltd. is unparalleled in the depth of its knowledge and understanding of the healthcare market.
Our firm stands for results, integrity and personal service, while providing access to business leaders at the highest level across the industry.
Since 1974, Strawn Arnold & Associates, Ltd. has focused entirely on the search for, and selection of, key talent for the pharmaceutical, biotechnology, medical device and diagnostics industries as well as for healthcare IT, services and provider organizations.
All of the Partners have held significant executive and line management positions with major health care companies in North America, Europe and Asia. Because they understand the business issues facing the health care industry, they can help define search parameters to maximize effort, decrease time-to-fill, and source top talent from within the industry.
In addition, our firm has the unique capability of offering insight and experience into every sector of the healthcare marketplace. In today’s diverging industry climate, our Partners provide a powerful solution for organizations that find themselves involved in multiple market sectors.
Since 2003 our firm has doubled in business size and scope of clients, thanks to a firmly established strong presence in medical devices as well as continued leadership positions in pharmaceutical and biotech. Currently our firm is one of the 20 largest boutique healthcare retained search firms in the United States. Recent clients range from billion-dollar, multinational pharmaceutical and medical device corporations to recently formed, venture-backed start-ups. In addition, increased focus on the growing needs in the healthcare IT, services and provider segments has added even greater depth to the firm’s clientele.
Life science and healthcare executive search firm Strawn Arnold & Associates has expanded with the additions of Tony Yost and Barry Duke as executive vice presidents. Mr. Yost has more than 30 years of pharmaceutical and diagnostic experience in both large and small companies. Most recently, he was chief commercial officer for Otonomy, a specialty pharmaceutical company, after
Life science and healthcare executive search firm Strawn Arnold & Associates has tapped R. Alberto Avendano, M.D., to serve as chief medical officer (CMO) of Osiris Therapeutics, Inc. Dr. Avendano brings to Osiris expertise in medical education and communication, academic and industry clinical research, pharmacovigilance and regulatory affairs. In his role as CMO, Dr. Avendano will manage and
Life science and healthcare executive search firm Strawn Arnold & Associates has added Jim Alexander as an executive vice president. With his practice focused in the pharma/biotech sector, Dr. Alexander is a seasoned pharmaceutical executive with 30 years of experience in the pharmaceutical and consumer products business, including significant experience at Pfizer and Warner-Lambert in business
Managing director Jeff Ashpitz has spent the last 17 years with Strawn Arnold & Associates, a leading life sciences recruiting specialist based in Austin. But it was his earlier corporate experience in life sciences, which lasted nearly 30 years, that set the groundwork for a storied career in executive search. In this interview, Jeff reveals
AUSTIN, TX, January 2, 2016 — Jim Alexander joined Strawn Arnold & Associates in 2016. He is a seasoned pharmaceutical executive with 30 years of experience in the pharmaceutical and consumer products business, including significant experience at Pfizer and Warner-Lambert in Business Development and Licensing, Marketing, Regulatory, and Medical Affairs. During his 10-year leadership of the Rutgers Post-Doctoral